Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuansong Bai

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Cancer Letters|February 1, 2025
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibodyJinguan Lin, Song Qu, Kunyu Yang, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancer Letters|February 1, 2025
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibodyJinguan Lin, Song Qu, Kunyu Yang, et al.
Cancer Communications (London, England)|June 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyXuezhi Hao, Lin Wang, Yanrong Hao, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 5